A favorable prognosis is associated with a number of differing immune factors such as: high levels of memory CD8+ T cells, high expression of Th1 cytokines, i.e., interferon gamma (IFN-γ) and IL-1, the development of a tertiary lymphoid structure (TLS) associated with the tumor, increased levels of cytotoxic mediators (granzymes, granulysin), low neutrophil–lymphocyte Ratio (NLR) and low to moderate vascularization of the tumor (75). The gene discussed is CD8A; the disease is neoplasm.